Skip to content

Citalopram Hydrobromide

FDA-approved product (tablet, oral), marketed as Celexa, Citalopram Hydrobromide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Citalopram Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Citalopram Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Depression and Traumatic Brain Injury

    NCT00254007 · start 2003-07

    Registered record
    Registry ID
    NCT00254007
    Conditions
    Depression; Traumatic Brain Injury
    Interventions
    citalopram (celexa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-07
    Completion
    2010-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Traumatic Brain Injury
    Interventioncitalopram (celexa)
    PhasePhase 4
    Registry statusCompleted
  • Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression

    NCT00157547 · start 2003-04

    Registered record
    Registry ID
    NCT00157547
    Conditions
    Major Depressive Disorder
    Interventions
    Selective serotonin reuptake inhibitors (SSRI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-04
    Completion
    2006-08
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionSelective serotonin reuptake inhibitors (SSRI)
    PhasePhase 4
    Registry statusCompleted
  • Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents

    NCT00249886 · start 2002-09

    Registered record
    Registry ID
    NCT00249886
    Conditions
    Major Depression
    Interventions
    Citalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2002-09
    Completion
    2006-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionCitalopram
    PhasePhase 3
    Registry statusWithdrawn
  • Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

    NCT00018902 · start 2001-01

    Registered record
    Registry ID
    NCT00018902
    Conditions
    Depression
    Interventions
    Fluoxetine; Venlafaxine; Cognitive Behavioral Therapy (CBT); Citalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-01
    Completion
    2007-03
    Enrolment
    334

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionFluoxetine; Venlafaxine; Cognitive Behavioral Therapy (CBT); Citalopram
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Citalopram vs Clomipramine vs Placebo in Recurrent Depression

    NCT01575158 · start 1997-10

    Registered record
    Registry ID
    NCT01575158
    Conditions
    Depression
    Interventions
    Citalopram; Clomipramine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-10
    Completion
    2007-09
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionCitalopram; Clomipramine; placebo
    PhaseNot applicable
    Registry statusCompleted